middle.news
Immuron Advances Oral IMM-529 to Combat Deadly C. difficile Infection
8:59am on Wednesday 8th of October, 2025 AEDT
•
Biotechnology
Read Story
Immuron Advances Oral IMM-529 to Combat Deadly C. difficile Infection
8:59am on Wednesday 8th of October, 2025 AEDT
Key Points
IND application submitted to FDA for IMM-529 clinical development
Phase 2 trial planned for first half of 2026 targeting CDI and recurrent CDI
IMM-529 employs a novel triple-target antibody approach against C. difficile
Market potential estimated at approximately US$400 million annually
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IMC
OPEN ARTICLE